Neoadjuvant and adjuvant therapy for invasive bladder tumours

Role of neoadjuvant chemotherapy in muscle-invasive bladder cancer: Clinical and cost effectiveness

“…Bladder cancer is the fifth most common cancer in the Western world, yet only the seventh in the ranking of cancer-related mortality. 1 Transitional cell carcinoma represents more than 90% of bladder cancers. The majority are superficial disease, but 40% will become muscle invasive.…”

“…The majority are superficial disease, but 40% will become muscle invasive. 1 This has different biological behaviour to superficial disease and is prognostically important, due to the metastatic potential. 2,3 Despite local therapy with cystectomy and/or radical radiotherapy, the 5-year survival rate of patients with muscle-invasive transitional cell carcinoma is approximately 50%.…”

Role of neoadjuvant chemotherapy in muscle-invasive bladder cancer: Clinical and cost effectiveness

“…Bladder cancer is the fifth most common cancer in the Western world, yet only the seventh in the ranking of cancer-related mortality. 1 Transitional cell carcinoma represents more than 90% of bladder cancers. The majority are superficial disease, but 40% will become muscle invasive.…”

“…The majority are superficial disease, but 40% will become muscle invasive. 1 This has different biological behaviour to superficial disease and is prognostically important, due to the metastatic potential. 2,3 Despite local therapy with cystectomy and/or radical radiotherapy, the 5-year survival rate of patients with muscle-invasive transitional cell carcinoma is approximately 50%.…”

Role of neoadjuvant chemotherapy in muscle-invasive bladder cancer: Clinical and cost effectiveness

“…Bladder cancer is the fifth most common cancer in the Western world, yet only the seventh in the ranking of cancer-related mortality. 1 Transitional cell carcinoma represents more than 90% of bladder cancers. The majority are superficial disease, but 40% will become muscle invasive.…”

“…The majority are superficial disease, but 40% will become muscle invasive. 1 This has different biological behaviour to superficial disease and is prognostically important, due to the metastatic potential. 2,3 Despite local therapy with cystectomy and/or radical radiotherapy, the 5-year survival rate of patients with muscle-invasive transitional cell carcinoma is approximately 50%.…”

Role of neoadjuvant chemotherapy in muscle-invasive bladder cancer: Clinical and cost effectiveness

“…Bladder cancer is the fifth most common cancer in the Western world, yet only the seventh in the ranking of cancer-related mortality. 1 Transitional cell carcinoma represents more than 90% of bladder cancers. The majority are superficial disease, but 40% will become muscle invasive.…”

“…The majority are superficial disease, but 40% will become muscle invasive. 1 This has different biological behaviour to superficial disease and is prognostically important, due to the metastatic potential. 2,3 Despite local therapy with cystectomy and/or radical radiotherapy, the 5-year survival rate of patients with muscle-invasive transitional cell carcinoma is approximately 50%.…”